Sector ETF Spotlight: $IBB Biotechnology on Drugs

bib biotechnology etf trading buy signal reversal chart investing

Biotechnology has traded basically sideways since the start of 2023.

In the face of higher rates, stronger dollar, inflation, FDA approvals and busts, and an emerging winter season, the ETF IBB has a serenity to it that appears drug-induced if you will.

Of the top 10 holdings, Regeneron is the big winner as of right now while Biogen is under pressure. Note-would keep your eyes on a potential bottoming pattern in BIIB.

  • Amgen Inc. 9.75%
  • Vertex Pharmaceuticals Incorporated 8.56%
  • Regeneron Pharmaceuticals, Inc. 8.11%
  • Gilead Sciences, Inc. 8.10%
  • IQVIA Holdings Inc 3.82%
  • Biogen Inc. 3.64%
  • Seagen, Inc. 3.46%
  • Moderna, Inc. 3.39%
  • Illumina, Inc. 2.59%
  • Mettler-Toledo International Inc. 2.53%

Furthermore, and even more interesting, is that the ETF does not really reflect the big movers. Rather, IBB is holding as a result but not flying.

Sign up for our FREE newsletter
and receive our best trading ideas and research

Is it time to buy IBB?

On the Daily chart and what is not shown here, is the July 6-month calendar range low at 124.11. 

Only once has IBB traded below that level in 2023 in March after the bank mini crisis.

Hence, we feel good calling 124 the bottom of the trading range and risk point.

The top of the trading range of the July 6-month indicator is 130.50. 

Again, IBB traded above that in early 2023 when it soared to 138.

However, since then, 130-132 has been resistance. We feel good calling that level the top of the trading range.

As far as other indicators, Real Motion looks like a double bottom from early July and now, although we would like to see more momentum.

On the weekly chart, we can say the same.

Our Leadership indicator shows IBB outperforming SPY on a daily timeframe, but still underperforming on a weekly basis.

On the price, over 128 will pique our interest.

Twitter: @marketminute

The author may have a position in mentioned securities at the time of publication. Any opinions expressed herein are solely those of the author and do not represent the views or opinions of any other person or entity.